Cloonan Michael 4
4 · Sionna Therapeutics, Inc. · Filed Oct 17, 2025
Insider Transaction Report
Form 4
Cloonan Michael
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2025-10-15$6.11/sh+14,775$90,275→ 562,118 total - Exercise/Conversion
Common Stock
2025-10-16$6.11/sh+200$1,222→ 547,543 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-15−14,775→ 163,367 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (14,775 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-16−10,225→ 153,142 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (10,225 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-16−200→ 152,942 totalExercise: $6.11Exp: 2032-03-01→ Common Stock (200 underlying) - Sale
Common Stock
2025-10-15$31.11/sh−14,775$459,662→ 547,343 total - Exercise/Conversion
Common Stock
2025-10-16$6.11/sh+10,225$62,475→ 557,568 total - Sale
Common Stock
2025-10-16$31.46/sh−10,225$321,691→ 547,343 total - Sale
Common Stock
2025-10-16$34.00/sh−200$6,800→ 547,343 total
Footnotes (4)
- [F1]This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.07 to $31.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date.